Brief: Cumberland Pharmaceuticals Receives FDA Fast Track Designation For Its Ifetroban Duchenne Muscular Dystrophy Program
04/02/2026 14:09
Feb 4 (Reuters) - Cumberland Pharmaceuticals Inc CPIX.O: CUMBERLAND PHARMACEUTICALS RECEIVES FDA FAST TRACK DESIGNATION FOR ITS IFETROBAN DUCHENNE MUSCULAR DYSTROPHY PROGRAM Source text: ID:nPn957JX4a Further company coverage: CPIX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cumberland Pharmaceuticals
See all newsBrief: Cumberland Pharmaceuticals Announces Assist-Ssc Trial Top-Line Results
Cumberland Pharmaceuticals Q2 loss widens after Apotex transaction
Brief: Cumberland Pharmaceuticals Announces Special Dividend Of $1.50 Per Share
Cumberland Pharmaceuticals Q1 revenue up 5%; to sell FDA‑approved brands to Apotex for $100 mln
NASDAQ RESUMED AT 09:38 AM